2月7日，蔚蓝生物获民生证券推荐评级，近一个月蔚蓝生物获得1份研报关注。
研报预计公司2023-2025年归母净利润分别为1.05、1.32、1.60亿元。研报认为，蔚蓝生物是国内较早布局酶制剂及益生菌相关领域的代表性企业，技术研发及平台优势突出。酶制剂及益生菌行业壁垒高、国产替代趋势明显，看好公司未来成长空间。
风险提示：市场竞争加剧、原材料价格波动、养殖疾病及自然灾害等。
- Headlines
- 蔚蓝生物获民生证券推荐评级，顺应大健康趋势，看好酶制剂、益生菌长期业务发展
蔚蓝生物获民生证券推荐评级，顺应大健康趋势，看好酶制剂、益生菌长期业务发展
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Hot News
Updated
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.